TaiGen Biotechnology: March 2026 Revenue Reaches 115 Million Yuan (Up 28.2% Year-on-Year)
NQ Score
1/100
N1 Content Completeness
0.8
AI Summary (NQ-processed)
TaiGen Biotechnology announced its March 2026 revenue of 115 million yuan, marking a significant 28.2% increase compared to the same period last year. This strong performance in the biotechnology and healthcare sector highlights the company's robust growth and expanding market presence.
AI Analysis
Frequently Asked Questions
- Q: What was TaiGen Biotechnology's revenue in March 2026?
- A: TaiGen Biotechnology's monthly revenue in March 2026 was 114,712 thousand yuan (approximately 115 million yuan).
- Q: What was the year-on-year revenue increase rate?
- A: The revenue increased by 28.2% compared to the same month last year.
- Q: What kind of business does TaiGen Biotechnology operate?
- A: TaiGen Biotechnology operates in the biotechnology and healthcare industry, focusing on the research, development, manufacturing, and sales of biopharmaceuticals.